PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34643201-6	2021	In vitro insulin secretion assay revealed that myricetin, luteolin, and apigenin were able to induce insulin secretion by human pancreatic cells (insulin production = 20.9 +- 1.3, 13.74 +- 1.8, and 11.33 +- 1.1 ng mL-1, respectively).	Luteolin	58-66	insulin	Homo sapiens	9-16	
34643201-6	2021	In vitro insulin secretion assay revealed that myricetin, luteolin, and apigenin were able to induce insulin secretion by human pancreatic cells (insulin production = 20.9 +- 1.3, 13.74 +- 1.8, and 11.33 +- 1.1 ng mL-1, respectively).	Luteolin	58-66	insulin	Homo sapiens	101-108	
34643201-6	2021	In vitro insulin secretion assay revealed that myricetin, luteolin, and apigenin were able to induce insulin secretion by human pancreatic cells (insulin production = 20.9 +- 1.3, 13.74 +- 1.8, and 11.33 +- 1.1 ng mL-1, respectively).	Luteolin	58-66	insulin	Homo sapiens	146-153	
35600955-8	2022	Results: The network pharmacology analysis showed that quercetin, luteolin, and kaempferol are the most significant active components in BHHD; STAT3, Jun, AKT1, MAPK3, MAPK1, and TP53 are the most critical drug targets; regulating hormones, reversing insulin (INS) resistance, exerting anti-inflammatory effects, and improving fertility might be the most important mechanisms of BHHD in the treatment of PCOS.	Luteolin	66-74	insulin	Homo sapiens	251-258